CTIS2023-505756-21-00招募中1 期
Pan-tumor neoadjuvant basket study of immune check-point inhibition and novel IO combinations (NEOASIS)
etherlands Cancer Institute0 个研究点目标入组 146 人开始时间: 2023年7月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 146
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Signed written informed consent, In case of pMMR tumors: no indication for neoadjuvant therapy according to standard of care, unless adjuvant treatment is considered a standard of care alternative, Patients at least 18 years of age, Non-metastatic dMMR and pMMR cancers either fitting within a specific basket or in the other” cohort (e.g. sarcoma, cervical cancer, head and neck cancers, anal cancer, esophageal SCC), Eligible for study biopsy, WHO performance status of 0 or 1, Screening laboratory tests must meet the following criteria and should be obtained within 7 days prior to randomization/registration: WBC > 2.0 x 10^9/L, ANC > 1.5x10^9/L, platelets > 100 x 10^9/L, Hemoglobin > 5.0mmol/L. Transfusion is allowed to obtain an adequate hemoglobin level. Liver function tests: total bilirubin < 1.5 upper limit of normal (ULN) (except for subjects with Gilbert syndrome, who can have total bilirubin <3.0 mg/dL); alkaline phosphatase <1.5ULN; transaminases (ASAT/ALAT) <3 x ULN; LDH < 1.5x ULN; Creatinine clearance (Cockcroft-Gault) of >45 ml/min, Albumin > 3.0 g/dL, Women of childbearing potential (WOCBP)* must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 20 weeks after the last dose of investigational drug; Non-childbearing potential is defined as: a. Postmenopausal: = 50 years of age and has not had menses for greater than 1 year. b. Amenorrheic for = 2 years without a hysterectomy and bilateral oophorectomy and afollicle-stimulating hormone value in the postmenopausal range upon prestudy( screening) evaluation. c. Status is post-hysterectomy, bilateral oophorectomy, or tubal ligation., Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of C1D1, Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving the study treatment and who are sexually active with WOCBP (excluding azoospermic men) will be instructed to adhere to contraception for a period of 28 weeks after the last dose of investigational drug and are not allowed to donate sperm during that timeframe.
排除标准
- •Signs of distant metastases on imaging and physical examination, No intercurrent illnesses, including but not limited to infections, unstable angina pectoris, Underlying medical conditions that, in the investigator’s opinion, will make the administration of the study drug hazardous or obscure the interpretation of toxicity determination of adverse events, Positive test for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection, History of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS);, Active autoimmune disease or a documented history of autoimmune disease, or other medical conditions requiring systemic steroid or immunosuppressive medications, except for subjects with vitiligo, diabetes mellitus type 1, hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis or resolved childhood asthma/atopy not requiring systemic treatment, Conditions requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease, Live vaccines in the 4 weeks prior to inclusion, Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, Current pregnancy or breastfeeding, Clinical obstruction, Clinical symptoms or radiological suspicion of perforation, Previous treatment with immune checkpoint inhibitors targeting including but not limited to CTLA-4, PD-1 or PD-L1, Prior chemotherapy for any cancer, Radiotherapy prior to surgery for disease under study, Active malignancies other than disease under study within 3 years prior to inclusion, except for malignancies with a negligible recurrence rate (e.g. <10% in 5 years);, History of allergy to study drug components, History of severe hypersensitivity reaction to any monoclonal antibody
研究者
相似试验
进行中（未招募）
2 期
A study to investigate if atezolizumab can reduce the size of urothelial cancer before surgery and to determine how the drug worksCancerISRCTN22771691Queen Mary University of London58
尚未招募
不适用
Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients with Resectable Gastrointestinal CancersNeoplasmsKCT0004253Asan Medical Center48
进行中（未招募）
1 期
A phase II study investigating use of the drug MPDL3280A before surgery in patients with rare subtypes of bladdercancer and urinary cancersEUCTR2019-004628-39-ESQueen Mary University of London58
进行中（未招募）
1 期
A phase II study investigating use of the drug MPDL3280A before surgery in patients with rare subtypes of bladder cancer and urinary cancersTumours of the urothelial tract requiring surgery (T1 high grade-T4a of the bladder, rare histological subtypes) and upper urinary tract (high grade or high risk)MedDRA version: 20.0Level: LLTClassification code 10046384Term: Ureteral cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10026426Term: Malignant neoplasm of renal pelvisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-004628-39-GBQueen Mary University of London58
已完成
不适用
Assessment of tumor response to immune checkpoint inhibitors using chest magnetic resonance imagingadvanced lung cancerJPRN-UMIN000023462Hamamatsu University School of Medicine20